Weighing the risks: @entity715 and @entity548 events in adults with XXXX and @entity299 .

@entity1 @entity548 @entity2067 @entity1031 @entity299 @entity715 @entity943
INTRODUCTION: @entity943 are associated to @entity1031 and anticoagulant treatment is installed according to risk profile. This study aimed to assess the rate of @entity715 events and major bleedings in adults with @entity299 ( @entity299 ) and @entity943 , as well as to determine the predictive value of specific clinical features and two risk scores for @entity1031 and @entity548 . METHODS AND RESULTS: In this retrospective study, a total of 229 adult @entity299 @entity1 with @entity943 , were included. Incidence and risk factors of @entity1031 were assessed in @entity1 without a mechanical valve (n=191), whereas @entity548 incidence and risk factors were studied in @entity1 receiving @entity2067 antagonists (n=164). In 13 @entity1 without a mechanical valve @entity715 events occurred, the first @entity715 event rate per year being 1.4%. A total of 29 @entity1 on @entity2067 antagonists suffered from major bleedings, at an annual first event rate of 4.4%. CHA2DS2-VASc score and HAS-BLED score predicted @entity1031 and @entity548 risk best in a dichotomized form. At a cut-off of >= 2 for high risk the rate of @entity715 events was 3.0% per year compared to 0.7% for a score of <2 (HR 3.7; 95%-CI 1.2-11.5; p=0.021). A major @entity548 rate of 10.8% per year was found in @entity1 on @entity2067 antagonists for HAS-BLED>= 2 as opposed to 3.5% with a score of <2 (HR 2.6; 95%-CI: 1.1-6.6; 0.017). CONCLUSION: In adult @entity299 @entity1 , @entity715 events and major bleedings are important complications of @entity943 and anticoagulant treatment. Assessment of @entity1031 and @entity548 risk in this @entity1 group can be performed with dichotomized CHA2DS2-VASc and HAS-BLED scores respectively.
